Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Recent advancements in identifying druggable molecular drivers in lung adenocarcinoma (LUAD), have transformed treatment paradigms. In recent years, Next Generation Sequencing (NGS) has gained momentum as an essential tool for in-depth simultaneous analysis of multiple genes, thereby streamlining the diagnostic process in LUAD. Despite this, the implementation of NGS testing in both the US and Europe remains suboptimal.
Aims: In compliance with a decree issued by the Italian Ministry of Health, Lombardy Region recently launched an initiative to implement NGS testing in patients with advanced LUAD. In this context, a real-world prospective observational study was planned to assess the efficacy of the regional network of molecular laboratories in testing nine biomarkers ( p.G12C, , mutations; , , , rearrangements), for on-label molecularly targeted drugs.
Results: In 2023, out of the 2784 advanced/metastatic LUAD patients expected in Lombardy, 2343 (84.2%) were successfully evaluated with an NGS panel including all the nine biomarkers for on-label drugs. Actionable aberrations were identified in 45.5% of the patients (1068/2343), predominantly involving , , and genes.
Conclusion: Our data provide evidence that establishing a structured network of NGS hubs is mandatory to ensure access of advanced LUAD patients to molecularly targeted treatments.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314203 | PMC |
| http://dx.doi.org/10.1177/03008916251341996 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification of Targetable Mutations in Ovarian Cancer.
JCO Precis Oncol
September 2025
Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA.
Purpose: mutations are classically seen in non-small cell lung cancers (NSCLCs), and EGFR-directed inhibitors have changed the therapeutic landscape in patients with -mutated NSCLC. The real-world prevalence of -mutated ovarian cancers has not been previously described. We aim to determine the prevalence of pathogenic or likely pathogenic mutations in ovarian cancer and describe a case of -mutated metastatic ovarian cancer with a durable response to osimertinib, an EGFR-directed targeted therapy.
View Article and Find Full Text PDFA phase IB study of binimetinib and palbociclib in molecularly selected advanced triple-negative breast cancer.
Cancer Res Commun
September 2025
Spanish National Cancer Research Centre, Madrid, Madrid, Spain.
Purpose: Advanced, pre-treated TNBC has a dismal prognosis and lacks effective options beyond standard cytotoxics. We previously showed, via phosphoproteomic screening, that CDK6 and ERK hyperactivation are linked to adverse outcomes and represent actionable targets. This prompted us to evaluate palbociclib and binimetinib in advanced TNBC after one or two prior therapies.
View Article and Find Full Text PDFFirst molecular phylogenetic and serological insights into infection in aborted ewes in Iraq: A cross-border comparative analysis.
Vet World
July 2025
Department of Veterinary Public Health, Veterinary Medicine College, University of Wasit, Wasit 52001, Iraq.
Background And Aim: is a significant zoonotic pathogen linked to reproductive losses in livestock and serious health risks in humans. In Iraq, listeriosis remains underreported in sheep, with limited data on its molecular and epidemiological characteristics. This study aimed to (1) estimate the seroprevalence of in recently aborted ewes, (2) evaluate the association between seropositivity and clinical indicators, and (3) perform molecular detection and phylogenetic analysis of polymerase chain reaction (PCR)-confirmed isolates.
View Article and Find Full Text PDFMechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity.
Nat Rev Cancer
September 2025
Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Neurotoxicity is a common and potentially severe adverse effect from conventional and novel cancer therapy. The mechanisms that underlie clinical symptoms of central and peripheral nervous system injury remain incompletely understood. For conventional cytotoxic chemotherapy or radiotherapy, direct toxicities to brain structures and neurovascular damage may result in myelin degradation and impaired neurogenesis, which eventually translates into delayed neurodegeneration accompanied by cognitive symptoms.
View Article and Find Full Text PDFPreclinical Investigations Toward Gd-free Molecularly Targeted Dual-Modal, MRI Dynamic (DCE-MRI)/Optical Imaging Contrast Agent for Cardiac Angiosarcoma.
Top Magn Reson Imaging
October 2025
BIOSPACE LAB, Nesles-la-Vallée, France.
Aims: Cardiac tumors are aggressive and asymptomatic in early stages, causing late diagnosis and locoregional metastasis. Currently, the standard of care uses gadolinium-based contrast agents for MRI, and the associated hypersensitivity reactions are a significant concern, such as gadolinium deposition disease. In addition, the proximity of cardiac lesions closer to vital structures complicates surgical interventions.
View Article and Find Full Text PDF